An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
The S&P 500 slipped 0.3% on Tuesday, Nov. 12, the benchmark index's first negative trading day since last week's election.
The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...
In an October 25 post on X (formerly Twitter), Kennedy warned current FDA officials: “If you work for the FDA and are part of ...
Daewoong Pharmaceutical announced on October 31 that it has signed a joint sales agreement with Celltrion Pharm to market CT-P41 ...
Another BiTE in development by Amgen binds CD3 on T cells to STEAP1 on prostate cancer ... has therapeutic potential for any ...
Mr. Karnani has more than 15 years of leadership experience in the life sciences industry. Over the course of nearly a decade at Horizon Therapeutics, Mr. Karnani held leadership positions spanning ...
Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback